Pyridine

Pyridine

SCHEMBL1460187

CCCCO.c1ccncc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
NAPRT Q6XQN6 1/20 0.45
LMNA P02545 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 2/20 0.35
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
MAPK1 P28482 1/20 0.32
CASP2 P42575 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
TBXAS1 P24557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL12476946 1.00 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Pyridine SCHEMBL8606542 0.98 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Pyridine SCHEMBL618965 0.98 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Benzene SCHEMBL6273750 0.98 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Pyridine SCHEMBL11779483 0.98 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Pyridine SCHEMBL10539991 0.95 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
1-Pentanol SCHEMBL27902508 0.93 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Pyridine SCHEMBL7422031 0.91 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
1-Pentanol SCHEMBL9404714 0.91 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT
Cetyl Alcohol SCHEMBL6680914 0.91 LMNA (0.59) ALDH1A1SMN1; SMN2TSHRTDP1NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108484487-B Antibacterial (methyl) acrylate monomer containing quaternary pyridinium salt and carbamate structure and preparation method and application thereof 华南理工大学 2021-10-22 CN claimed
CN-111233748-A Synthesis of tirofiban hydrochloride 海门慧聚药业有限公司 2020-06-05 CN claimed
CN-102285912-A Method for preparing N-n-butylsulfonyl-O-(4-(4-pyridyl)-butyl)-L-tyrosine alkyl ester 2011-12-21 CN claimed
CN-102260208-A New preparation process of 4-pyridine butanol 2011-11-30 CN claimed
US-20040072790-A1 Safe natural pharmaceutical composition for treating cancer LIU YAGUANG (US) 2004-04-15 US claimed
US-5834605-A SOLVENT EXTRACTION OF DAIDZIN AND GENISTIN FROM PUERARIA OR SOYBEAN SEEDS; VACUUM DISTILLATION, CHROMATOGRAPHY USING FIRST A BUTANOL AND THEN A BUTANOL/PYRIDINE DEVELOPER, AND RECRYSTALLIZATION LIU YAGUANG (US) 1998-11-10 US claimed
US-4985408-A PRODUCING PUERARIN FROM PLANT ROOTS LIU YAGUANG (US) 1991-01-15 US claimed
US-4133804-A MULTISTAGE, DIALYSIS, FILTRATION AND CHROMATOGRAPHING OF BLOOD SERUM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1979-01-09 US claimed
CN-115947680-B Tirofiban intermediate compound and preparation method thereof 山东新时代药业有限公司 2025-09-23 CN disclosed
CN-115181058-B Composition and quality control method thereof 武汉武药科技有限公司 2024-06-11 CN disclosed
CN-115947680-A Tirofiban intermediate compound and preparation method thereof 山东新时代药业有限公司 2023-04-11 CN disclosed
WO-2023038506-A1 COMPOSITION CONTAINING FOXTAIL EXTRACT AS ACTIVE INGREDIENT, AND USE THEREOF 경북대학교 산학협력단 2023-03-16 WO disclosed
WO-2023038287-A1 COMPOSITION, FOR PREVENTING, RELIEVING, OR TREATING MUSCLE WEAKNESS-RELATED DISEASE, COMPRISING CELERY SEED EXTRACT AS ACTIVE INGREDIENT 경북대학교 산학협력단 2023-03-16 WO disclosed
CN-115772116-A Tirofiban intermediate compound 山东新时代药业有限公司 2023-03-10 CN disclosed
US-4312857-A ANALGESICS, ANTIDEPRESSANTS, SEDATIVES, TRANQUILIZERS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE VETERANS ADMINISTRATION (US) 1982-01-26 US disclosed
US-4162305-A Antibiotic XK-99 and process for production thereof ABBOTT LABORATORIES (US) 1979-07-24 US disclosed
US-4148886-A TREATMENT OF AUTOIMMUNE DISEASES Institute National de la Sante & de la Recherche Medicale (INSERM) (FR) 1979-04-10 US disclosed
US-4133804-A MULTISTAGE, DIALYSIS, FILTRATION AND CHROMATOGRAPHING OF BLOOD SERUM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1979-01-09 US disclosed
US-4107424-A ANTIBACTERIAL ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1978-08-15 US disclosed
US-4021387-A PARASITICIDES, ANAPHYLAXIS, BRONCHIAL ASTHMA PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1977-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072790-A1 Safe natural pharmaceutical composition for treating cancer MATR3, HPN, HAMP ALDH1A1 1635/4885SMN1; SMN2 4152/4885TSHR 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.